1 Failure to Induce Global/Clinical Remission |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
1.1 MMX mesalazine 4.8 g versus 2.4 g/day |
2 |
194 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.82, 1.29] |
1.2 Salofalk 4.5 g versus 3 g/day |
1 |
213 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.35 [0.96, 1.89] |
1.3 Salofalk 4.5 g versus 1.5 g/day |
1 |
209 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.69, 1.22] |
1.4 Salofalk 3 g versus 1.5 g/day |
1 |
210 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.49, 0.95] |
1.5 Pentasa 4 g versus 2.25 g/day |
1 |
123 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.77, 1.08] |
1.6 Asacol 3.6 g versus 2.4 g/day |
1 |
131 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.79 [0.61, 1.04] |
2 Failure to Induce Global/Clinical Remission or Improvement |
9 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
2.1 Asacol 4.8 g versus 2.4 g/day |
3 |
1459 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.89 [0.78, 1.01] |
2.2 MMX mesalazine 4.8 g versus 2.4 g/day |
1 |
169 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.61, 1.33] |
2.3 Asacol 4.8 g versus 1.6 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.36 [0.19, 0.69] |
2.4 Asacol 3.6 g versus 2.4 g/day |
2 |
179 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.48, 0.97] |
2.5 Asacol 3.6 g versus 1.2 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.61 [0.29, 1.28] |
2.6 Asacol 2.4 g versus 1.6 or 1.2 g/day |
2 |
155 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.92 [0.70, 1.21] |
2.7 Pentasa 4 g versus 2.25 g/day |
1 |
123 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.44 [0.27, 0.71] |
3 Development of any adverse event |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
3.1 Asacol 4.8 g versus 1.6 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.76 [0.48, 1.21] |
3.2 Salofalk 4.5 g versus 3 g/day |
1 |
213 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.78, 1.20] |
3.3 Salofalk 4.5 g versus 1.5 g/day |
1 |
209 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.77, 1.19] |
3.4 Salofalk 3 g versus 1.5 g/day |
1 |
213 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.84, 1.29] |
3.5 Pentasa 4 g versus 2.25 g/day |
1 |
123 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.78, 1.11] |
4 Withdrawal from study due to adverse event |
5 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
4.1 Asacol 4.8 g versus 2.4 g/day |
1 |
268 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.24, 3.63] |
4.2 Asacol 4.8 g versus 1.6 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.02, 4.26] |
4.3 Asacol 2.4 g versus 1.6 g/day |
1 |
106 |
Risk Ratio (M‐H, Fixed, 95% CI) |
5.0 [0.25, 101.73] |
4.4 Salofalk 4.5 g versus 3 g/day |
1 |
213 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [0.50, 3.36] |
4.5 Salofalk 4.5 g versus 1.5 g/day |
1 |
209 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.80 [0.34, 1.84] |
4.6 Salofalk 3 g versus 1.5 g/day |
1 |
210 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.61 [0.25, 1.52] |
4.7 Pentasa 4 g versus 2.25 g/day |
1 |
123 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.21 [0.01, 4.28] |
5 Exclusions and withdrawals after entry |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
5.1 Asacol 4.8 g versus 2.4 g/day |
1 |
386 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.68 [0.40, 1.16] |
5.2 Asacol 4.8 g versus 1.6 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.19 [0.04, 1.01] |
5.3 Asacol 3.6 g versus 2.4 g/day |
1 |
48 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.5 [0.10, 2.48] |
5.4 Asacol 3.6 g versus 1.2 g/day |
1 |
49 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.42 [0.09, 1.95] |
5.5 Asacol 2.4 g versus 1.6 or 1.2 g/day |
2 |
155 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.60, 1.92] |
5.6 Salofalk 4.5 g versus 3 g/day |
1 |
213 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.59, 1.74] |
5.7 Salofalk 4.5 g versus 1.5 g/day |
1 |
209 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.62 [0.38, 0.99] |
5.8 Salofalk 3 g versus 1.5 g/day |
1 |
210 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.61 [0.38, 0.99] |
5.9 Pentasa 4 g versus 2.25 g/day |
1 |
123 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.53 [0.24, 1.14] |